2021-04-09 · Vaxart Inc NASDAQ Updated Apr 9, 2021 11:58 PM. VXRT 5.53 0.14 (2.47%). Post-Market 0.01 (0.18%)

Find the latest Vaxart, Inc. - Common Stock (VXRT) stock quote, history, news and other vital information to help you with your stock trading and investing.

The Company develops and markets oral flu vaccines that engages in the immune system of the gut to generate systemic and mucosal immune responses. Which institutional investors are buying and selling shares of Vaxart (NASDAQ:VXRT) stock? View the most recent institutional ownership activity and 13F transactions for VXRT stock at MarketBeat. Vaxart Stock Trades Higher On Increased Volume: A Technical Analysis - Benzinga benzinga.com - March 16 at 6:31 PM: Vaxart: The ‘Show Me’ Story Still Has Potential, Says Analyst - Yahoo Finance finance.yahoo.com - March 11 at 10:45 PM: Vaxart: The ‘Show Me’ Story Still Has Potential, Says Analyst finance.yahoo.com - March 11 at 10:45 PM A high-level overview of Vaxart, Inc. (VXRT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. Vaxart (NASDAQ:VXRT) The company is working on a vaccine for the novel coronavirus that works via tablets instead of injection. If Vaxart reports positive results from this clinical trial, investors will likely see shares of VXRT stock soar higher. Shares of Vaxart Inc. tumbled 42.9% in premarket trading on Wednesday after the company said its oral COVID-19 vaccine candidate was well-tolerated in a Phase 1 clinical trial but it did not Vaxart (NASDAQ:VXRT) had an amazing run in 2020. The tiny biotech started off the year as a micro-cap stock, but when the COVID-19 pandemic struck, it -- like many vaccine-related stocks -- took off.

Should I buy Vaxart, Inc. (VXRT)? Use the Zacks Rank and Style Scores to find out is VXRT is right for your portfolio.

Earnings for Vaxart are expected to grow in the coming year, from ($0.35) to ($0.30) per share. Price to Earnings Ratio vs. the Market. The P/E ratio of Vaxart is -9.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Price to …

Vaxart Inc. (NASDAQ: VXRT) shares gained 2.69% Tuesday on increased volume, closing the session at $7.06.

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Description: Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. Vaxart (NASDAQ:VXRT) The company is working on a vaccine for the novel coronavirus that works via tablets instead of injection. If Vaxart reports positive results from this clinical trial, investors will likely see shares of VXRT stock soar higher. Shares of Vaxart Inc. tumbled 42.9% in premarket trading on Wednesday after the company said its oral COVID-19 vaccine candidate was well-tolerated in a Phase 1 clinical trial but it did not Vaxart (NASDAQ:VXRT) had an amazing run in 2020.
Lack sprayburk

Rooms Shows Rankings Earnings Calendar Shop.

The stock was trending on StockTwits, and there was no company evident news to explain the volume increase.
Jobb åhlens

argumentation om abort
kbt terapi vasteras
streckkod ean 128
dermatolog farsta
swedish name that start with m
jordbruksverket djurvårdare nivå 2

Vaxart Inc. NASDAQ:VXRT 1:52:16 PM EDT. 6.91. +0.17 (+2.52%). See the Insiders for Another Symbol Search. Twitter Share Facebook Share StockTwits

Vaxart Inc. (NASDAQ: VXRT) shares gained 2.69% Tuesday on increased volume, closing the session at $7.06. The stock was trending on StockTwits, and there was no company evident news to explain the volume increase. Vaxart reported a net loss of $9.0 million for the second quarter of 2020 compared to $5.6 million for the second quarter of 2019. The increase was mainly due to an increase in operating expenses.

Militärpolis lön
jag är en astronaut linus wahlgren

Vaxart Inc. (NASDAQ: VXRT) shares gained 2.69% Tuesday on increased volume, closing the session at $7.06. The stock was trending on StockTwits, and there was no company evident news to explain the volume increase.

Thinking about buying stock in Northern Dynasty Minerals, Checkpoint Therapeutics, Rigel Pharmaceuticals, Vaxart, or Aytu Bioscience?